Overview

Memantine for Recurrent Glioblastoma

Status:
Terminated
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if a medication called memantine is effective in treating glioblastoma. Memantine targets a specific receptor, called a glutamate receptor, which is thought to be involved in the growth of brain tumors. It has previously been studied for other types of conditions, such as Alzheimer's disease, but it has not yet been evaluated in the treatment of brain tumors. The investigators will also be determining how common it is for patients with brain tumors to have side effects to memantine. Memantine will be taken by mouth twice a day.
Phase:
Phase 2
Details
Lead Sponsor:
University of Rochester
Treatments:
Memantine